Premium
Chronic wound state exacerbated by oxidative stress in Pax 6 +/− aniridia‐related keratopathy
Author(s) -
Ou J,
Walczysko P,
Kucerova R,
Rajnicek AM,
McCaig CD,
Zhao M,
Collinson JM
Publication year - 2008
Publication title -
the journal of pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.964
H-Index - 184
eISSN - 1096-9896
pISSN - 0022-3417
DOI - 10.1002/path.2371
Subject(s) - pax6 , oxidative stress , wound healing , corneal epithelium , myofibroblast , transcription factor , cancer research , microbiology and biotechnology , biology , pathology , immunology , medicine , epithelium , endocrinology , genetics , fibrosis , gene
Heterozygosity for the transcription factor PAX 6 causes eye disease in humans, characterized by corneal opacity. The molecular aetiology of such disease was investigated using a Pax 6 +/− mouse model. We found that the barrier function of uninjured Pax 6 +/− corneas was compromised and that Ca 2+ –PKC/PLC–ERK/p38 signalling pathways were abnormally activated, mimicking a ‘wounded’ epithelial state. Using proteomic analysis and direct assay for oxidized proteins, Pax 6 +/− corneas were found to be susceptible to oxidative stress and they exhibited a wound‐healing delay which could be rescued by providing reducing agents such as glutathione. Pax6 protein was oxidized and excluded from the nucleus of stressed corneal epithelial cells, with concomitant loss of corneal epithelial markers and expression of fibroblast/myofibroblast markers. We suggest a chronic wound model for Pax6‐related corneal diseases, in which oxidative stress underlies a positive feedback mechanism by depleting nuclear Pax6, delaying wound healing, and activating cell signalling pathways that lead to metaplasia of the corneal epithelium. The study mechanistically links a relatively minor dosage deficiency of a transcription factor with potentially catastrophic degenerative corneal disease. Copyright © 2008 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.